Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified August 2012 by National Health Research Institutes, Taiwan
Sponsor:
Information provided by (Responsible Party):
National Health Research Institutes, Taiwan
ClinicalTrials.gov Identifier:
NCT01668732
First received: August 16, 2012
Last updated: August 17, 2012
Last verified: August 2012
  Purpose

Heroin addiction has emerged as a serious problem with tremendous impacts on the addicts and the society. Since the introduction of opioids substitutive treatment in 2006, more than 30,000 heroin addicts had received treatment, and nearly 12,000 continued on treatment currently. However, an unknown proportion of patients hidden in community remained un-treatment. To motivate the community heroin addicts is thus a challenging task.

It is suggested that decision making deficit is core feature which determine outcomes and treatment motivations in patients with addiction disorders. Recently, the state-of-the-art development of epigenetics uncover that environmental modification, via altering level of DNA methylation and gene expression will influence on neurocognitive functioning.

Via respondent-driven sampling, this study aims to recruit a representative sample targeting at the hard-to-reach community heroin addicts. The goal of this study is to identify the clinical feature as well as decision making-related neurocognitive deficit in these patients. Moreover, the investigators will explore the interplay of clinical features, DNA methylation and gene expressions on opioids receptor genes. The findings will help to clarify the clinical characteristics of community heroin addicts, to uncover the links between DNA methylation and clinical features of heroin addiction and to develop modifiable treatment targets in the future.


Condition
Heroin Addiction

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts

Resource links provided by NLM:


Further study details as provided by National Health Research Institutes, Taiwan:

Estimated Enrollment: 1
Study Start Date: August 2012
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts
community heroin addicts

  Eligibility

Ages Eligible for Study:   20 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

community heroin addicts

Criteria

Inclusion Criteria:

  • 1) 20 to 65 of age; 2) meeting DSM-IV criteria of opioids dependence

Exclusion Criteria:

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01668732

Contacts
Contact: Sheng Chang Wang, M.D., M.Sc. 886-37-246166 ext 36703 scwang69@gmail.com

Sponsors and Collaborators
National Health Research Institutes, Taiwan
Investigators
Principal Investigator: Sheng Chang Wang, M.D., M.Sc. National Health Research Institute, Taiwan
  More Information

No publications provided

Responsible Party: National Health Research Institutes, Taiwan
ClinicalTrials.gov Identifier: NCT01668732     History of Changes
Other Study ID Numbers: MD101SCW01
Study First Received: August 16, 2012
Last Updated: August 17, 2012
Health Authority: Taiwan: National Health Research Institutes

Additional relevant MeSH terms:
Heroin Dependence
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders

ClinicalTrials.gov processed this record on September 30, 2014